Related Experiment Video
Updated: Oct 10, 2025
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
Suitability of Metastatic Lung Tumors for Stereotactic Body Radiotherapy
Takahisa Eriguchi1,2,3, Nobuhiro Tsukamoto1, Atsuhiro Kumabe1
1Department of Radiation Oncology, Saiseikai Yokohamashi Tobu Hospital, Yokohama, Japan.
Abstract:
We investigated factors influencing local control of lung metastases treated with stereotactic body radiotherapy (SBRT) and determined the type of lesions for which SBRT is more suitable. Ninety-six patients and 196 tumors were included. Median follow-up duration was 32.0 months (range 4.7-95.8). The two-year local recurrence rate was 15.2% (95% confidence interval: 10.2-21.3). Multivariate analysis revealed biological effective dose, ultracentral tumor location, reirradiation, and prior chemotherapy as significant factors. SBRT is suitable for lung metastases, especially for peripheral tumors and those located in the inner lung parenchyma. For ultracentral lesions and recurrent lesions after SBRT, metastasectomy is recommended.
